Are you a medical practitioner? Yes, then you must be aware of Minnesota-based one of the world’s leading medical technology giant Medtronic plc (MDT - Free Report) which has a global reach that extends to roughly 160 countries. Last year, more than 70 million people benefited from Medtronic’s medical therapies, which treat cardiac and vascular diseases, diabetes, and neurological and musculoskeletal conditions.
Currently, Medtronic has a Zacks Rank #3 (Hold) but that could change following its positive third-quarter fiscal 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The current Zacks Consensus Estimate stands at $1.16 per share. Medtronic’s adjusted earnings per share of $1.17 exceeded this estimate by a penny.
Revenues: Medtronic posted revenues of $7.37 billion, beating the Zacks Consensus Estimate for revenues of $7.20 billion.
Medtronic plc Price and EPS Surprise
Key Stats: Revenues from Medtronic’s Cardiac and Vascular Group rose 7% at constant exchange rate (CER) to $2.80 billion, revenues from Minimally Invasive Therapies Group increased 6% at CER to $2.04 billion. Also, revenues from Restorative Therapies Group rose 5% at CER to $1.94 billion, while revenues from Diabetes Group rose 13% at CER to $584 million.
Major Factors: Per management, third quarter performance was encouraging. Moreover, the company witnessing growth in all the business segments also buoys optimism.
Stock Price: Following the earnings release, share prices declined by a 0.06% in the pre-market trading session till now.
Check back later for our full write up on Medtronic's earnings report later!
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Are you a medical practitioner? Yes, then you must be aware of Minnesota-based one of the world’s leading medical technology giant Medtronic plc (MDT - Free Report) which has a global reach that extends to roughly 160 countries. Last year, more than 70 million people benefited from Medtronic’s medical therapies, which treat cardiac and vascular diseases, diabetes, and neurological and musculoskeletal conditions.
Currently, Medtronic has a Zacks Rank #3 (Hold) but that could change following its positive third-quarter fiscal 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The current Zacks Consensus Estimate stands at $1.16 per share. Medtronic’s adjusted earnings per share of $1.17 exceeded this estimate by a penny.
Revenues: Medtronic posted revenues of $7.37 billion, beating the Zacks Consensus Estimate for revenues of $7.20 billion.
Medtronic plc Price and EPS Surprise
Key Stats: Revenues from Medtronic’s Cardiac and Vascular Group rose 7% at constant exchange rate (CER) to $2.80 billion, revenues from Minimally Invasive Therapies Group increased 6% at CER to $2.04 billion. Also, revenues from Restorative Therapies Group rose 5% at CER to $1.94 billion, while revenues from Diabetes Group rose 13% at CER to $584 million.
Major Factors: Per management, third quarter performance was encouraging. Moreover, the company witnessing growth in all the business segments also buoys optimism.
Stock Price: Following the earnings release, share prices declined by a 0.06% in the pre-market trading session till now.
Check back later for our full write up on Medtronic's earnings report later!
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on MDT - FREE